Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

Ottawa Hospital Research Institute

$374,850.00

Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: A Pilot Randomized Controlled Trial - CONQUER-DVT Pilot Trial

FY 2022-23

Summary
Inflammation defends the human body against invading microbes. The formation of blood clots in the veins of the leg (deep vein thrombosis) causes undesired inflammation leading to harmful consequences. As a result, almost one in two people experiences the so-called "post-thrombotic syndrome" after blood clots. This condition leads to swelling and pain in the leg, which can progress to leg ulceration and immobility. To date, there is no treatment that can help prevent or cure post-thrombotic syndrome. Colchicine is a very safe and cheap medication that blocks inflammation. This oral tablet has been already used for decades to cure several diseases in which inflammation causes harmful consequences. In addition, recent large studies demonstrated that a low dose of colchicine can be well tolerated and beneficial if taken once a day after the formation of a blood clot in the heart. Our goal is to evaluate whether a study assessing if these anti-inflammatory tablet can be safe and effective to reduce the harmful effects of inflammation and post-thrombotic syndrome after deep vein thrombosis is feasible. To answer our research question, we plan to include in our study 150 patients from 5 Canadian centers. The proposed treatment is very promising as it has been already proven to be safe and effective in conditions where undesired inflammation after other types of blood clot causes harm. Moreover, if supported by the results of our full study, the proposed medication, colchicine, could be quickly used all around the world as it is widely available and very cheap.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
480053
Name
Carrier Marc
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Randomized Controlled Trials 2
Projecttitle
Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: A Pilot Randomized Controlled Trial - CONQUER-DVT Pilot Trial
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$374,850
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Clotting Defects/Thrombosis; Colchicine; Deep Vein Thrombosis; Inflammation; Pilot Study; Post Thrombotic Syndrome; Randomized Controlled Trial; Venous Thromboembolism
Abstract
Inflammation defends the human body against invading microbes. The formation of blood clots in the veins of the leg (deep vein thrombosis) causes undesired inflammation leading to harmful consequences. As a result, almost one in two people experiences the so-called "post-thrombotic syndrome" after blood clots. This condition leads to swelling and pain in the leg, which can progress to leg ulceration and immobility. To date, there is no treatment that can help prevent or cure post-thrombotic syndrome. Colchicine is a very safe and cheap medication that blocks inflammation. This oral tablet has been already used for decades to cure several diseases in which inflammation causes harmful consequences. In addition, recent large studies demonstrated that a low dose of colchicine can be well tolerated and beneficial if taken once a day after the formation of a blood clot in the heart. Our goal is to evaluate whether a study assessing if these anti-inflammatory tablet can be safe and effective to reduce the harmful effects of inflammation and post-thrombotic syndrome after deep vein thrombosis is feasible. To answer our research question, we plan to include in our study 150 patients from 5 Canadian centers. The proposed treatment is very promising as it has been already proven to be safe and effective in conditions where undesired inflammation after other types of blood clot causes harm. Moreover, if supported by the results of our full study, the proposed medication, colchicine, could be quickly used all around the world as it is widely available and very cheap.
Competitiondate
202303
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Carrier, Marc; Kahn, Susan R; Le Gal, Grégoire; Shivakumar, Sudeep P; Siegal, Deborah M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $374,850~ $0~